Trevi Therapeutics (TRVI) PT Raised to $10 at Needham & Company on Haduvio Data, "Valuation Discounts Potential"
Tweet Send to a Friend
Needham & Company analyst Serge Belanger raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $10.00 (from $8.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
